Randomization and placebo effects in clinical trials of major depressive disorder by James A. Rogers, Stephen Senn

Get full text

A note on the probability structure of a doubly randomized delayed start design by Zhao Yang

Subjects: Get full text

Comparison of Different Machine Learning Methodologies for Predicting the Non‐Specific Treatment Response in Placebo Controlled Major Depressive Disorder Clinical Trials by Roberto Gomeni, Françoise Bressolle‐Gomeni

Subjects: Get full text

Commentary: The immediate pain relief of low-level laser therapy for burning mouth syndrome: a retrospective study of 94 cases by Takayuki Suga, Akira Toyofuku

Subjects: Get full text

The economic impact of next-generation stadiums: evidence from the Juventus Stadium using synthetic control methodology by Valerio Antolini

Subjects: Get full text

Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment by Annabelle M Belcher, Thomas O Cole, Aaron D Greenblatt, Stephen W Hoag, David H Epstein, Michael Wagner, Amy S Billing, Ebonie Massey, Kristen R Hamilton, Zofia K Kozak, Christopher J Welsh, Eric Weintraub, Emerson M Wickwire, Eric D Wish, Ted J Kaptchuk, Luana Colloca

“…Long recognised for its capacity to enhance treatment outcomes for a wide range of neuropsychiatric disorders including pain, the placebo effect offers an as-yet untested avenue to such an enhancement. …”
Get full text

A Review of Herbal Treatment for Functional Gastrointestinal Disorders and Infection by Krupavaram B, A Kishore Babu, Santhiya Manickam Pillay, Tan Ching Siang, Bama V. V. Menon, Ganesh Sritheran Paneerselvam, Long Chiau Ming, Yaser Mohammed Al-Worafi, Wen Han Chooi

“…We summarise the research supporting the effectiveness of non-herbal dyspepsia treatment, considering factors beyond acid reduction, such as the placebo effect and the variability of dyspepsia symptoms, as discussed in the section on proton pump inhibitor (PPI) medication. …”
Get full text

Kinesiology Tape: A Descriptive Survey of Healthcare Professionals in the United States by Scott W Cheatham, Russell T Baker, Thomas E Abdenour

“…Some respondents believed KT only created a placebo effect (40%) and use it for such therapeutic purposes (58%). …”
Get full text

Personality Differences of Brain Networks in Placebo Analgesia and Nocebo Hyperalgesia: A Psychophysiological Interaction (PPI) Approach in fMRI by Yu Shi, Shimin Huang, Hongrui Zhan, Yaping Wang, Yanyan Zeng, Guiyuan Cai, Jianming Yang, Wen Wu

“…We designed this study to explore the personality differences of functional magnetic resonance imaging (fMRI) signals in placebo response and nocebo response by using psychophysiological interaction (PPI) analysis. 30 healthy subjects underwent conditioning induction training to establish expectations of placebo effect and nocebo effect, and then, all subjects completed the following experimental procedures: (1) baseline scanning, (2) acute pain model establishment, (3) pain status scanning, and (4) pseudorandom scanning of block design of placebo response or nocebo response. …”
Get full text

Electroacupuncture for mild-to-moderate dry eye: study protocol for a multicentre, randomised, single-blind, sham-controlled trial by Yue Zhao, Guang Yang, Yun-Qiong Lu, Mei-Yan Li, Jue Hong, Yan-Ting Yang, Xue-Jun Wang, Xie-He Kong, Zhao Ma, Xin-Yun Huang, Yue-Lan Zou, Xing-Tao Zhou, Xiao-Peng Ma

“…Clinical evidence shows that electroacupuncture (EA) can improve DE symptoms, tear secretion and tear film stability, but it remains controversial whether it is just a placebo effect. We aim to provide solid clinical evidence for the EA treatment of DE.Methods and analysis This is a multicentre, randomised, sham-controlled trial. …”
Get full text

Should the Food and Drug Administration Limit Placebo-Controlled Trials? by Max Goodman, Connor Pedersen

“…Extreme care must be taken to avoid abuse of this option.[4] The FDA has largely ignored this and deemed placebo controls the gold standard, stating that “PCTs are necessary to control for placebo effect of investigational medicinal product.”[5] The FDA has even refused to approve drugs that are tested against established treatments instead of against placebos, notably atenolol.[6] By stretching the “methodological” exception and failing to define harm reasonably, the FDA does not meet the spirit behind Helsinki’s conditions for allowing PCTs. …”
Get full text

Impact of Nasal Anatomical Variation Subtype on Surgical Outcomes for Rhinogenic Contact Point Headache by Salvatore Lavalle, Annalisa Pace, Giuseppe Magliulo, Mario Lentini, Jerome Rene Lechien, Christian Calvo-Henriquez, Federica Maria Parisi, Giannicola Iannella, Antonino Maniaci, Daniela Messineo

“…The efficacy of surgical versus medical management has been debated, with some studies showing excellent long-term outcomes but others citing placebo effects. This study aimed to clarify the correlation with nasal anatomical variation detected by CT and RCPH treatment outcomes. …”
Get full text